Sionna Therapeutics, a Boston, MA-based life sciences company developing differentiated treatments for cystic fibrosis (CF), closed a $111m Series B financing.
The round was led by OrbiMed with participation from funds advised by T. Rowe Price Associates, Inc., Q Healthcare Holdings, LLC., a wholly owned subsidiary of QIA, the sovereign wealth fund of Qatar, and previous investors including RA Capital, TPG’s The Rise Fund, Atlas Venture, and the Cystic Fibrosis Foundation.
The company, which has raised approximately $150m to date, intends to use the funds to advance development of a franchise of small molecules targeting NBD1 and complementary modulators, including NBD1’s interface with the intracellular loop 4 (ICL4) region and the transmembrane domain 1 (TMD1) of CFTR. Sionna plans to submit Investigational New Drug applications (IND) for its first NBD1 targeted program, SION-638, and for its lead ICL4 program, SION-109, within the next 12 months.
Led by Mike Cloonan, President and Chief Executive Officer, Charlotte McKee, M.D., Chief Medical Officer, John Macor, Ph.D., Chief Scientific Officer, Elena Ridloff, Chief Financial Officer, Greg Hurlbut, Ph.D., Co-founder, Senior Vice President, Discovery Research, and Mark Munson, Ph.D., Co-founder, Vice President, Medicinal Chemistry, Sionna Therapeutics is a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. The company is advancing a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is defective in CF, by stabilizing CFTR’s first nucleotide-binding domain (NBD1).
The company’s Board of Directors includes:
- Josh Resnick, M.D., Chair, Managing Director, RA Capital
- Bruce Booth, D.Phil., Partner, Atlas Venture
- Mike Cloonan, President & CEO, Sionna Therapeutics
- Lucian Iancovici, M.D., Managing Director, TPG Life Sciences Innovation
- Adam Rosenberg, J.D., Venture Partner, RA Capital
- Peter Thompson, M.D., Partner, OrbiMed
FinSMEs
21/04/2022